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intubationAbstract Purpose: The present study compared the efficacy of two different doses of labetalol, for
attenuation of hemodynamic response to laryngoscopy and intubation in hypertensive patients.
Patients and methods: 75 hypertensive patients, aged 18–60 years undergoing elective surgical pro-
cedures, require general anesthesia and orotracheal intubation. Patients were allocated to any of the
three groups (25 each), Group C (control) 5 ml 0.9% saline. Group L1 (labetalol) 0.15 mg/kg
diluted with 0.9% saline to 5 ml. Group L2 (labetalol) 0.3 mg/kg diluted with 0.9% saline to
5 ml. In the control group 5 ml of 0.9% saline was given i.v. 5 min prior to intubation. In the L1
group 0.15 mg/kg of labetalol was given i.v. 5 min prior to intubation. In the L2 group 0.3 mg/
kg of labetalol was given i.v. 5 min prior to intubation. All the patients were subjected to the same
standard anesthetic technique. Heart rate (HR), systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were recorded prior to induction, at time of intubation and 1, 3, 5, and 10 min after
intubation. Mean arterial pressure (MAP) and rate pressure product (RPP) were calculated.
Results: Compared to placebo both the doses of labetalol (0.15 mg/kg) and (0.3 mg/kg) signifi-
cantly attenuated the rise in heart rate, systolic blood pressure, and RPP during laryngoscopy
and intubation. However, the difference was not statistically significant between both doses of labe-
talol at intubation, 1 min, 3 min and 10 min post-intubation.
Conclusion: Both doses of labetalol (0.15 mg/kg and 0.3 mg/kg) attenuate hemodynamic response
to laryngoscopy and intubation in dose dependent manner.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Increases in heart rate and blood pressure are the principal
changes in the cardiovascular system during laryngoscopy
and tracheal intubation. Stimulus of the laryngeal and tracheal
340 R. Kumar et al.tissues may also cause increases in both sympathetic and
sympatho-adrenal reflex activities [1,2]. Hemodynamic changes
are generally temporary without any sequelae. However, these
changes can facilitate and accelerate the development of
myocardial ischemia, arrhythmia, infarction and cerebral hem-
orrhage in patients with coronary artery disease, hypertension
or cerebrovascular disease [3,4]. Different pharmacologic
agents such as lidocaine, vasodilator agents inhibiting
sympatho-adrenal response, a- and ß-adrenergic blockers, opi-
oids and calcium channel blockers can be administered prior to
tracheal intubation in order to prevent hemodynamic
responses [5–10].
Labetalol is an unique oral and parenteral antihypertensive
drug that is a1- and nonselective b1- and b2-adrenergic antag-
onist. It reaches its peak effect at 5–15 min after intravenous
(IV) injection and rapidly redistributes (5.9 min redistribution
half-life). It lowers BP by decreasing systemic vascular resis-
tance (a1-blockade), whereas reflex tachycardia triggered by
vasodilatation is attenuated by simultaneous b-blockade. Car-
diac output remains unchanged [11–19]. The aim of the present
study was to compare the efficacy of two different doses of
labetalol for controlling these hemodynamic responses to
laryngoscopy and tracheal intubation under the same anes-
thetic techniques in hypertensive patients.
2. Patients and methods
This study was a prospective, randomized, placebo controlled,
double-blinded trial comparing two different doses of labetalol
in decreasing the hemodynamic response during rigid laryn-
goscopy and intubation. The protocol was approved by the
Institutional Review Board and was in accordance with Inter-
national Conference on Harmonization; Good Clinical Prac-
tice (ICH-GCP) standards.
Sample size was calculated by power analysis, using a two-
sample t test, with a two-sided type I error of 5% (a= 0.05)
and power at 80.37 (a= 0.19). Therefore, 75 patients, ASA
physical status I and II, aged 18–60 years, undergoing elective
surgical procedures, requiring general anesthesia and orotra-
cheal intubation were included in the study. Informed consent
was obtained from all the patients. According to the diagnostic
criteria of the Joint National Committee on Hypertension
(JNC-8), hypertension was defined if systolic blood pressure
was >140 mmHg and/or diastolic blood pressures were
>90 mmHg. During pre-anesthetic evaluation patients were
identified who are hypertensive but their hypertension was con-
trolled by antihypertensive drugs such as calcium channel
antagonists (e.g., nifedipine, nicardipine, diltiazem) and renin-
angiotensin inhibitors (e.g., captopril) for varying periods of
time. None had a history of myocardial ischemia or infarction,
nor had an abnormal ECG on admission to the hospital.
Patients with cardiovascular, pulmonary, hepatic, and renal
disease; those on B blockers; patients with difficult airway;
laryngoscopy and intubation time more than 20 s, or requiring
more than two attempts were excluded from the study.
The patients were randomly (computer generated random-
ization schedule) allocated into one of the three groups, of 25
each. Blinding was done using the sequentially numbered opa-
que sealed envelope (SNOSE) technique. Patients were kept nil
orally for 8 h prior to surgery and morning dose of anti-
hypertensive drugs was given at 6 am with sips of water onthe day of the surgery. All patients were premedicated intra-
venously 10 min prior to induction with inj. ondansetron
0.1 mg/kg, and inj. midazolam 0.05 mg/kg. In a double blind
manner, one 5 ml syringe was prepared for each patient.
Group L1 – Syringe contained Labetalol (0.15 mg/kg
diluted with 0.9% saline to 5 ml).
Group L2 – Syringe contained Labetalol (0.3 mg/kg diluted
with 0.9% saline to 5 ml).
Group C – Syringe contained 5 ml of 0.9% saline.
After recording the baseline parameters, patients were pre-
oxygenated with 100% O2 by a face mask for 3 min and then
study drug was administered iv five minutes before intubation.
Anesthesia was induced with 5 mg kg1 thiopentone iv, and
loss of the eyelash reflex was confirmed followed by
0.1 mg kg1 vecuronium iv. Direct laryngoscopy with a stan-
dard Macintosh laryngoscope blade for tracheal intubation
was initiated five minute after administration of study drug.
None received topical lidocaine and opioids before laryn-
goscopy for tracheal intubation. All intubations were per-
formed by the first author, and were accomplished within
20 s. Tracheal tubes of ID 7.0 mm and 8.0 mm were used for
female and male patients, respectively. After tracheal intuba-
tion, anesthesia was maintained with 4 L min1 nitrous oxide,
2 L min1 oxygen and isoflurane 1.0% and intermittent
boluses of I mg vecuronium bromide. Manual ventilation of
the lungs was adjusted to maintain an end-tidal CO2 tensions
between 35 mmHg and 40 mmHg as measured by an anes-
thetic/respiratory gas analyzer (AS/3TM, Datex, Helsinki, Fin-
land). At the end of surgery, neuromuscular blockade was
reversed with inj. neostigmine (40 lg/kg) and inj. glycopyrro-
late (10 lg/kg). Heart rate, systolic blood pressure (SBP),
and diastolic blood pressure (DBP) were recorded prior to
induction, at time of intubation and 1, 3, 5, and 10 min after
intubation. Mean arterial pressure (MAP) and rate pressure
product (RPP) were calculated for the same time stations.
Abnormal ECG changes were also recorded.
2.1. Statistical analysis
Statistical analysis was performed using the SPSS software ver-
sion 20 (Chicago, IL, USA). Patient demographics were com-
pared with analysis of variance (ANOVA). The study data
were analyzed using statistical methods of mean, standard
deviation, paired students ‘‘t” test (for values within the group
at different time stations) and independent samples ‘‘t” test
(for comparison of intergroup values). All values were
expressed as mean ± SD. P< 0.05 was considered as signifi-
cant (S) and P> 0.05 as statistically non-significant (NS).
3. Results
The patients in the three groups were comparable with respect
to age, weight, sex, and duration of surgery or anesthesia
(Table 1).
The pre-induction values of heart rate (HR) were compara-
ble between groups with no significant difference (Table 2).
There was statistically significant difference in HR throughout
study time between the L1 and control group (P< 0.001), and
L2 and control group (P< 0.001). At intubation, 1 min, 3 min
Table 1 Demographic data.
Group L1
(n= 25)
Group L2
(n= 25)
Group C
(n= 25)
Age (yr) 42 ± 10 41 ± 12 42 ± 12
Sex (female/male) 18/7 19/6 19/6
Height (cm) 155 ± 10 156 ± 12 154 ± 11
Weight (kg) 52 ± 10 51 ± 11 50 ± 11
Antihypertensive medication
– Calcium channel
blocker
13 10 11
– Renin-angioten-
sin inhibitor
12 15 14
Mean values ± SD or number. L1 = labetalol (0.15 mg/kg),
L2 = labetalol (0.3 mg/kg) C = control.
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nificantly different in the L1 and L2 group (P> 0.05). At
5 min post intubation, there was significant difference in HR
between L1 and L2 groups (P< 0.001).
The pre-induction values of SBP were comparable between
groups with no significant difference (Table 3). Compared with
the control group values SBP was significantly lower at all time
stations in the L1 (P< 0.001) and L2 group (P< 0.001).
There were no significant difference in SBP between L1 and
L2 at intubation and 1 min post-intubation (P> 0.05). How-
ever, there was statistically significant difference in SBP
between L1 and L2 group at 3 min, 5 min and 10 min post
intubation (P< 0.001).
The pre-induction values of DBP were comparable between
groups with no significant difference (Table 3). Compared with
the control group values DBP was significantly lower at all
time stations in the L1 (P< 0.001) and L2 group
(P< 0.001). There was no significant difference in DBP
between L1 and L2 at intubation and 1 min post-intubation.
However, there was statistically significant difference in DBP
between L1 and L2 group at 3 min, 5 min and 10 min post
intubation (P< 0.001) (see Table 4).
The pre-induction values of MAP were comparable
between groups with no significant difference (Table 5).
MAP was significantly high at the time of intubation in the
control group compared with L1 (P< 0.001) and L2 group
(P< 0.001). Intubation and 1 min post intubation values were
comparable between the L1 and L2 group and not statistically
significant (P> 0.05). However, there were statistically signif-
icant difference in MAP values between L1 and L2 group at
3 min, 5 min and 10 min post intubation (P< 0.001).Table 2 Heart rate.
HR Group C Group L1 Group L2
Pre-induction 83.64 ± 6.0 82.44 ± 6.3 84.24 ± 6
At intubation 109.40 ± 6.3 96.20 ± 7.0 93.72 ± 5
I min post-intubation 104.20 ± 6.1 96.24 ± 6.5 94.40 ± 5
3 min post-intubation 93.64 ± 4.4 88.08 ± 6.2 86.68 ± 5
5 min post-intubation 86.36 ± 3.4 81.60 ± 6.3 75.04 ± 1
10 min post-intubation 78.60 ± 4.5 72.16 ± 6.8 69.04 ± 9
Mean value ± SD.The pre-induction values of RPP were comparable between
groups with no significant difference (Table 6). RPP was signif-
icantly less at the time of intubation in the L1 and L2 group
(P< 0.001) as compared to the control group. Intubation
and 1 min post intubation values were comparable between
the L1 and L2 group and not statistically significant
(P> 0.05). However, there was statistically significant differ-
ence in RPP values between L1 and L2 group at 3 min,
5 min and 10 min post intubation (P< 0.00).
4. Discussion
Hypertensive patients are more prone to greater cardiovascu-
lar responses to laryngoscopy and tracheal intubation than
are normotensive patients. Fox et al. reported two hyperten-
sive patients in whom complications, including pulmonary
edema, cardiac failure and cerebrovascular hemorrhage, fol-
lowed hypertensive episodes directly related to tracheal intuba-
tion. Thus, transitory increases in AP and HR are probably of
no consequence in healthy individuals, but either or both may
be dangerous to those with hypertension, myocardial insuffi-
ciency, or cerebrovascular disease. Therefore, the prevention
of these hemodynamic changes following tracheal intubation
is of particular importance in hypertensive patients [3,9–11].
Hemodynamic response to laryngoscopy and intubation
begins immediately after tracheal intubation and reaches max-
imum value within one minute. Therefore, timing of drug
administration and their peak effect, used for attenuation of
hemodynamic response, should correspond to those of hemo-
dynamic response. The onset of action of labetalol 2–3 min
and peak effect reaches at 5–15 min [14]. We studied the hemo-
dynamic response to laryngoscopy and intubation for a period
of 10 min as this is the average period for which hemodynamic
response to laryngoscopy and intubation are believed to last
[14,16].
The adverse cardiovascular changes and catecholamine dis-
charge seen during laryngoscopy and tracheal intubation
appear in two phases. The effects of laryngoscopy should be
distinguished from effects seen while the endotracheal tube is
placed through the trachea. Shribman et al. showed the differ-
ences between these two events. Even with stable anesthesia,
laryngoscopy alone without intubation can cause a supraglot-
tic stimulus. As a result, both systolic blood pressure (SBP)
and diastolic blood pressure (DBP) increase in contrast to
the measurements before induction. However, no significant
increase in HR occurs during laryngoscopy. Increase in BP is
due to norepinephrine, while increase in HR is due to epi-
nephrine discharge. Infraglottic stimulus caused by placingP value C & L1 P value C & L2 P value L2 & L1
.4 (P> 0.05) (P> 0.05) (P> 0.05)
.6 P< 0.001 P< 0.001 (P> 0.05)
.2 P< 0.001 P< 0.001 (P> 0.05)
.3 P< 0.001 P< 0.001 (P> 0.05)
0.9 P< 0.001 P< 0.001 P< 0.001
.9 P< 0.001 P< 0.001 (P> 0.05)
Table 3 Systolic blood pressure.
SBP Group C Group L1 Group L2 P value C & L1 P value C & L2 P value L2 & L1
Pre-induction 132 ± 5.5 131.44 ± 1.5 133.04 ± 5.0 (P> 0.05) (P> 0.05) (P> 0.05)
At intubation 162.16 ± 13.0 145.88 ± 6.7 144.88 ± 6.0 P< 0.001 P< 0.001 (P> 0.05)
I min post intubation 152.72 ± 12.0 139.96 ± 5.4 136.80 ± 5.8 P< 0.001 P< 0.001 (P> 0.05)
3 min post-intubation 140.92 ± 8.3 131.68 ± 5.2 121.80 ± 9.4 P< 0.001 P< 0.001 P< 0.001
5 min post-intubation 136.28 ± 5.6 123.24 ± 8.6 111.92 ± 11.6 P< 0.001 P< 0.001 P< 0.001
10 min post-intubation 129.64 ± 6.6 111.60 ± 8.2 104.20 ± 7.0 P< 0.001 P< 0.001 P< 0.001
Mean value ± SD.
Table 4 Diastolic blood pressure.
DBP Group C Group L1 Group L2 P value C & L1 P value C & L2 P value L2 & L1
Pre-induction 82.60 ± 5.2 82.40 ± 5.0 81.72 ± 4.9 (P> 0.05) (P> 0.05) (P> 0.05)
At intubation 102.56 ± 3.8 93.0 ± 5.1 91.0 ± 5.2 P< 0.001 P< 0.001 (P> 0.05)
I min post-intubation 104.40 ± 7.9 89.48 ± 8.4 86.40 ± 11.4 P< 0.001 P< 0.001 (P> 0.05)
3 min post-intubation 114.01 ± 4.1 100.56 ± 86.8 93.21 ± 7.0 P< 0.001 P< 0.001 P< 0.001
5 min post-intubation 94.28 ± 5.6 81.88 ± 4.4 71.36 ± 9.3 P< 0.001 P< 0.001 P< 0.001
10 min post-intubation 82.20 ± 7.5 72.84 ± 5.2 67.88 ± 7.5 P< 0.001 P< 0.001 P< 0.001
Mean value ± SD.
Table 5 Mean arterial pressure.
MAP Group C Group L1 Group L2 P value C & L1 P value C & L2 P value L2 & L1
Pre-induction 99.25 ± 4.6 98.75 ± 4.5 98.83 ± 4.4 (P> 0.05) (P> 0.05) (P> 0.05)
At intubation 122.43 ± 6.0 110.63 ± 4.9 108.96 ± 4.4 P< 0.001 P< 0.001 (P> 0.05)
I min post-intubation 120.51 ± 7.6 106.31 ± 5.4 103.20 ± 8.4 P< 0.001 P< 0.001 (P> 0.05)
3 min post-intubation 114.01 ± 4.1 100.19 ± 8.6 93.21 ± 7.0 P< 0.001 P< 0.001 P< 0.001
5 min post-intubation 108.28 ± 4.7 95.67 ± 4.0 84.88 ± 8.8 P< 0.001 P< 0.001 P< 0.001
10 min post-intubation 98.00 ± 6.0 85.64 ± 4.4 80.00 ± 6.3 P< 0.001 P< 0.001 P< 0.001
Mean value ± SD.
Table 6 Rate pressure product (RPP).
RPP Group C Group L1 Group L2 P value C & L1 P value C & L2 P value L2 & L1
Pre-induction 11097.12 ± 993.9 10835.12 ± 921.5 11200.88 ± 878.0 (P> 0.05) (P> 0.05) (P> 0.05)
At intubation 17756.48 ± 1948.2 14037.28 ± 1279.0 13571.20 ± 895.4 P< 0.001 P< 0.001 (P> 0.05)
I min post-intubation 15936.16 ± 1766.5 3455.92 ± 861.94 12911.20 ± 875.3 P< 0.001 P< 0.001 (P> 0.05)
3 min post-intubation 13210.44 ± 1179.0 11596.32 ± 927.3 10565.44 ± 1116.9 P< 0.001 P< 0.001 P< 0.001
5 min post-intubation 11771.36 ± 717.7 10062.40 ± 1125.8 8481.20 ± 1787.5 P< 0.001 P< 0.001 P< 0.001
10 min post-
intubation
10185.04 ± 741.1 8054.24 ± 974.4 7219.68 ± 1290.5 P< 0.001 P< 0.001 P< 0.001
Mean value ± SD.
342 R. Kumar et al.the endotracheal tube occurs in phase two. In this situation, an
extra cardiovascular response and catecholamine discharge
occur. Stress response increases at this stage and both SBP
and DBP measurements increase by 36–40% in contrast to
control levels. HR levels increase more than 20% with tracheal
intubation in contrast to laryngoscopy [20–21].
The present study has demonstrated that iv administration
of labetalol in two different doses attenuates the increases inMAP and RPP after laryngoscopy and tracheal intubation.
Levels of RPP > 20,000 are more commonly associated with
angina and myocardial ischemia [9]. In the present study, the
RPP after tracheal intubation was 17756.48 in Group C
(Table 6), but these critical increases in RPP were avoided in
Groups L1 and L2. Furthermore, the changes from baseline
values in RPP immediately after tracheal intubation in Group
L1 and L2 were significantly less than those in Group C. The
Attenuation of hemodynamic response to laryngoscopy and intubation in hypertensive patients 343differences in these changes of RPP following tracheal intuba-
tion may be attributed to the differences in those of HR.
Tachycardia causes more stress effect on the heart than
increases in BP. This effect can be due to the increase in
myocardial oxygen requirement, decreased diastolic filling,
and reduction in the time needed for effective coronary circu-
lation. Tachycardia accompanied with hypertension increases
the existing ischemia risk in patients with coronary artery dis-
ease [9].
Values of group L1 and L2 when compared with their pre-
operative values (Tables 2 and 5) show insignificant rise
(P> 0.05) in heart rate and MAP at the time of intubation
as compared to placebo group. Increases in HR and MAP at
intubation in the placebo group were 30% and 23%, respec-
tively, in the L1 group, 16% and 12% and L2 group 11%
and 11% respectively. Our results corroborate well with the
finding of Amar et al. who administered 0.15 mg/kg of labeta-
lol for induction and 0.25–0.3 mg/kg for maintenance of anes-
thesia in a study investigating its effects on perioperative stress.
Increases in HR and MAP at intubation in the placebo group
were 33% and 52%, respectively, and in the labetalol group,
7.3% and 21.3%, respectively [22]. Kim et al. reported that a
single dose of labetalol of dosage 0.25 mg/kg given preopera-
tively 5 min before intubation decreases HR significantly after
intubation up to 10 min [17]. Roelofse et al. found that labeta-
lol of dosage 1 mg/kg given as an IV bolus 1 min before laryn-
goscopy was not effective in the attenuation of HR. This
failure of the study can be explained by the different time of
administration of the study drug because labetalol has peak
effect after 5–10 min [23].
There was statistically significant difference in HR between
L1 and L2 group at 5 min post intubation (P< 0.00). Simi-
larly, there was statistically significant difference in SBP,
DBP, MAP and RPP between L1 and L2 group at 3 min,
5 min and 10 min post intubation (P< 0.00). These may
because of higher dose of labetalol used in L2 (0.3 mg/kg)
group as compared to L1 (0.15 mg/kg) group.
The only side effect observed was that of group L2 (0.3 mg/
kg) in form of bradycardia, intraoperatively. Seven patients
(28%) developed bradycardia (pulse rate <50 beats per min-
ute) after the study period of 10 min and atropine in 0.2 mg
increments (max. 0.01 mg/kg) was given. All the patients
responded to atropine treatment. There were no recurrent epi-
sodes of bradycardia. Transient premature ventricular contrac-
tions appeared immediately after tracheal intubation in two
patients who received placebo saline. These arrhythmias did
not need any treatment. Thus, there were no serious complica-
tions after laryngoscopy and tracheal intubation in patients
who had received labetalol at both the doses. To conclude,
Labetalol in both the doses 0.15 mg/kg and 0.3 mg/kg iv is
effective in reducing the hemodynamic responses to direct
laryngoscopy and tracheal intubation in dose dependent man-
ner in hypertensive patients. However bradycardia is more
common in patients who are receiving labetalol in dose of
0.3 mg/kg. Further studies are needed to elucidate the compar-
ative effects of both doses of labetalol in large number of
patients.
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